The present disclosure is generally related to a device for minimally invasive treatment of human tricuspid valve regurgitation.
Tricuspid valve regurgitation is a condition evidenced by leakiness of the tricuspid valve, which is the valve between the upper and lower chambers of the right side of the heart. An individual exhibiting tricuspid valve regurgitation will have blood leak backwards through the tricuspid valve each time the right ventricle contracts. More particularly, when the right ventricle contracts to pump blood toward the lungs, some of the blood leaks backward into the right atrium. This increases the volume of blood in the atrium, which can cause the right atrium to enlarge. Enlargement of the right atrium can result in a change in the pressure in both the nearby heart chambers and adjacent blood vessels.
Functional tricuspid valve regurgitation is the most common type of valve pathology and is usually associated with mitral valve disease. Currently, the majority of patients with both mitral valve disease and tricuspid valve regurgitation receive surgical treatment for the mitral valve only. Tricuspid valve regurgitation is most often under-diagnosed and/or ignored. Asymptotic dilation of the tricuspid annulus may benefit from repair independent of regurgitation. Without treatment for tricuspid dilation, mitral valve disease can lead to biventricular failure and even death.
Thus, a device and method for a minimally invasive treatment of human tricuspid valve regurgitation is needed.
An embodiment of a device for minimally invasive medical treatment comprising: a hollow tube comprising: a first end; a second end; an exterior having a plurality of cutouts, wherein the cutouts allow the hollow tube to be flexible; at least one snap mechanism configured to connect the first end and the second end together; and one or more anchors configured to extend outward from the exterior.
Aspects, features, benefits and advantages of the embodiments described herein will be apparent with regard to the following description, appended claims, and accompanying drawings where:
This disclosure is not limited to the particular systems, devices and methods described, as these may vary. The terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope.
As used in this document, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Nothing in this disclosure is to be construed as an admission that the embodiments described in this disclosure are not entitled to antedate such disclosure by virtue of prior invention. As used in this document, the term “comprising” means “including, but not limited to.”
As discussed herein, the existing treatment for tricuspid valve regurgitation is invasive and potentially dangerous. For example, current treatment may include repair methods such as DeVega Repair and utilization of annuloplasty rings or tricuspid rings that require open heart surgery. Open heart surgery may introduce several comorbidities in addition to any existing conditions. Thus, many patients who suffer from tricuspid valve regurgitation may not be appropriate candidates for open heart surgery, and would therefore greatly benefit from a new device and/or method for percutaneous or minimally invasive treatment of tricuspid valve regurgitation.
An implant and delivery system for introduction of a semi-rigid ring for treatment of tricuspid valve regurgitation includes a tricuspid annuloplasty ring comprising an outer hollow member with a plurality of segments. In a further embodiment, segments may be adjustable and may cooperate with one another in order to change the outer hollow member from an elongated insertion shaped geometry to an annular operable shaped geometry. The tricuspid annuloplasty ring may include one or more zones comprising internal anchor members located at least partially within the outer hollow member. In one non-limiting embodiment, the tricuspid annuloplasty ring may include up to four different anchor zones, which are further discussed herein. In an embodiment, the internal anchor members may be configured to emerge sequentially from windows (i.e., openings) along the hollow tube, thereby engaging the tissue of the tricuspid valve annulus under treatment, potentially in a predetermined sequence.
Disclosed herein are various embodiments related to minimally invasive or percutaneous trans-catheter delivery of a tricuspid ring. In addition, an embodiment may comprise methods for reducing or adjusting the dimension between the anterior and septal leaflets and/or reducing or adjusting the dimension between the anteroposterior commissure to septal leaflet, thereby minimizing or eliminating the issue of tricuspid valve regurgitation.
The illustrated example embodiments will be best understood by reference to the figures. The following description is intended only by way of example, and simply illustrates certain example embodiments.
Referring to
As would be understood by one skilled in the art, the AV node 104 is a part of the electrical conduction system of the heart that coordinates the top of the heart. The AV node 104 is an area of specialized tissue between the atria and the ventricles of the heart, specifically in the posteroinferior region of the interatrial septum near the opening of the coronary sinus, which conducts the normal electrical impulse from the atria to the ventricles. Puncturing or introducing any impulse into this node causes adverse effects such as Arrhythmia, irregular heart rhythm, and, in the worst, case heart failure. Therefore, in an embodiment, the design of a tricuspid ring may not include anchors in the segment of the ring that will be located adjacent to the AV node.
In
In an embodiment, as shown by the schematic diagram in
Referring now to
Fluorinated ethylene propylene or FEP is a copolymer of hexafluoropropylene and tetrafluoroethylene. It differs from polytetrafluoroethylene resins in that it is melt-processable using conventional injection molding and screw extrusion techniques. Moreover, it has a very low coefficient of friction and thus, in an embodiment, may make an exceptional material to serve as an anchor track and/or anchor the assemblies within the laser cut Ni—Ti rings. FEP provides various benefits over current methods, such require a significant pulling force to retrieve a metal end of a metal ring, particularly one that has a bend radius, after deployment from a catheter. In contrast, an embodiment may utilize an FEP tube that is laser cut and allows easy sliding of the anchor assembly within the laser cut Ni—Ti ring.
FEP is very similar in composition to the fluoropolymers PTFE (polytetrafluoroethylene) and PFA (perfluoroalkoxy polymer resin). FEP and PFA both share PTFE's useful properties of low friction and non-reactivity, but are more easily formable. FEP is softer than PTFE and melts at 260° C. It is also highly transparent and resistant to sunlight.
As shown in
Referring now to
Additionally or alternatively,
Referring now to
Referring to
A further embodiment, as illustrated in
As discussed herein, various embodiments may employ an anchor stop (e.g., 1704). The need for an anchor stop arises from the fact that the anchors may move after a tricuspid ring is deployed from the catheter (e.g., in linear shape) and takes on the “D” shape, as discussed herein. Specifically, the anchor assemblies that were held stationary when the ring was held in a linear position (e.g., the anchors held beneath and adjacent to the windows in the laser cut tube) may start moving and emitting prematurely from the windows because of the bend radius of the ring.
Thus, in order to combat premature deployment, which may render the ring useless and cause serious issues during the procedure, an embodiment utilizes the anchor stops to hold the anchors in place until the ring has reached its final location and deployment is appropriate. Once the assembly has reached its final location, the anchor stop may be overcome when an operator pulls a suture that is connected to the anchor assembly and forces the assembly and its stopper to slide, thus deploying the anchor systems, in the method discussed herein. Generally, an anchor stop is a bump geometrical feature, or step that prevents the anchor assembly from moving when the ring is deployed out of the delivery system; however, various embodiments and configurations are discussed herein and shown in the corresponding figures.
In another embodiment, illustrated in
Additionally or alternatively, as shown in
Referring now to
As discussed herein, an embodiment may take the shape of the memory hypotube and may have an operable geometry, for example, an annular and/or D shaped geometry (as shown in
Referring now to
Thus, as shown in
A detailed view of an embodiment where the snapping mechanism is in a closed configuration is shown in
A detailed view of the female part 3401 of the snapping mechanism 3400 according to one embodiment is shown in
A detailed view of the male part 3405 of the snapping mechanism according to an embodiment is shown in
Turning now to
As shown in
In some embodiments, such as that shown in
In another embodiment, as shown in
In another embodiment, as shown in
As shown in
Additionally or alternatively,
Referring now to
Accordingly, systems and methods are provided for introducing a tricuspid ring (e.g. while it is housed in a linear shape within the delivery system) in a trans-apical or trans-femoral approach. In an embodiment, the distal tip of the delivery system may be introduced above the tricuspid annulus. Once the tricuspid ring is introduced, the plane of the tricuspid ring may be rotated (e.g., automatically) to be parallel to the plane of the tricuspid annulus.
The tricuspid ring may then be snapped into a proper shape (e.g., a “D” shape) and introduced to the stabilization tool. The shape is possible because, as discussed herein, the tricuspid ring comprises an outer hollow member with a plurality of segments, wherein the segments may be adjustable and may cooperate with one another in order to change the outer hollow member from an annular operable shaped geometry to an elongated insertion shaped geometry and vice versa.
Once the tricuspid ring is properly controlled by the stabilization tool (e.g., as depicted in
In a further embodiment, the anchored tricuspid ring is anchored towards the septal leaflet, thereby reducing the height of the anterior-septal leaflets by approximately 15% to 20%. One or more second anterior zone anchors may also be deployed. In another embodiment, the design of the tricuspid ring may not include anchors in certain zones (e.g., the AV node zone). As discussed herein, this may be due to a particular zone being sensitive to external forces which could lead to adverse effects for the patient such as Arrhythmia, an irregular heart rhythm or heart failure.
Additionally or alternatively, the tricuspid ring (e.g., the septal zone and the posterior zone) may be dragged by the stabilizing tool to reduce the height of the anterior-septal leaflet height prior to the anchors in the first and second anterior zones one and two being applied.
In the above detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be used, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.
The present disclosure is not to be limited in terms of the particular embodiments described in this application, which are intended as illustrations of various aspects. Many modifications and variations can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the appended claims. The present disclosure is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled. It is to be understood that this disclosure is not limited to particular methods, reagents, compounds, compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity.
It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (for example, bodies of the appended claims) are generally intended as “open” terms (for example, the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” et cetera). While various compositions, methods, and devices are described in terms of “comprising” various components or steps (interpreted as meaning “including, but not limited to”), the compositions, methods, and devices can also “consist essentially of” or “consist of” the various components and steps, and such terminology should be interpreted as defining essentially closed-member groups. It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present.
For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (for example, “a” and/or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations.
In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (for example, the bare recitation of “two recitations,” without other modifiers, means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, et cetera” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (for example, “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, et cetera). In those instances where a convention analogous to “at least one of A, B, or C, et cetera” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (for example, “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, et cetera). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”
In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, et cetera. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, et cetera. As will also be understood by one skilled in the art all language such as “up to,” “at least,” and the like include the number recited and refer to ranges that can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.
Various of the above-disclosed and other features and functions, or alternatives thereof, may be combined into many other different systems or applications. Various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art, each of which is also intended to be encompassed by the disclosed embodiments.
The present application claims benefit of priority under 35 U.S.C. 119(e) to the filing date of U.S. Provisional Patent Application 62/375,079 filed Aug. 15, 2016, entitled, “DEVICES AND METHODS FOR THE TREATMENT OF HEART VALVE INSUFFICIENCIES,” the contents of which is incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4602911 | Ahmadi et al. | Jul 1986 | A |
5236440 | Hlavacek | Aug 1993 | A |
5306296 | Wright et al. | Apr 1994 | A |
5695518 | Laerum | Dec 1997 | A |
5716370 | Williamson, IV et al. | Feb 1998 | A |
5855614 | Stevens et al. | Jan 1999 | A |
6113611 | Allen et al. | Sep 2000 | A |
6231602 | Carpentier et al. | May 2001 | B1 |
6619291 | Hlavka et al. | Sep 2003 | B2 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6669687 | Saadat | Dec 2003 | B1 |
6689048 | Vanden Hoek et al. | Feb 2004 | B2 |
6726704 | Loshakove et al. | Apr 2004 | B1 |
6776784 | Ginn | Aug 2004 | B2 |
6790229 | Berreklouw | Sep 2004 | B1 |
6797002 | Spence et al. | Sep 2004 | B2 |
6805711 | Dugan et al. | Oct 2004 | B2 |
6893459 | Macoviak | May 2005 | B1 |
7101395 | Tremulis et al. | Sep 2006 | B2 |
7114953 | Wagner | Oct 2006 | B1 |
7175660 | Cartledge et al. | Feb 2007 | B2 |
7238191 | Bachmann | Jul 2007 | B2 |
7285087 | Moaddeb et al. | Oct 2007 | B2 |
7297150 | Cartledge et al. | Nov 2007 | B2 |
7569072 | Berg et al. | Aug 2009 | B2 |
7594887 | Moaddeb et al. | Sep 2009 | B2 |
7635329 | Goldfarb et al. | Dec 2009 | B2 |
7655040 | Douk et al. | Feb 2010 | B2 |
7717954 | Solem et al. | May 2010 | B2 |
7722668 | Moaddeb et al. | May 2010 | B2 |
7758637 | Starksen et al. | Jul 2010 | B2 |
7837729 | Gordon et al. | Nov 2010 | B2 |
7988725 | Gross et al. | Aug 2011 | B2 |
8163014 | Lane et al. | Apr 2012 | B2 |
8182529 | Gordon et al. | May 2012 | B2 |
8236049 | Rowe et al. | Aug 2012 | B2 |
8287591 | Keidar et al. | Oct 2012 | B2 |
8518107 | Tsukashima et al. | Aug 2013 | B2 |
8579968 | Shannon et al. | Nov 2013 | B1 |
9180008 | Yellin et al. | Nov 2015 | B2 |
9402721 | Buchbinder et al. | Aug 2016 | B2 |
9433503 | Tsukashima et al. | Sep 2016 | B2 |
20020151961 | Lashinski et al. | Oct 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020188170 | Santamore et al. | Dec 2002 | A1 |
20030050693 | Quijano et al. | Mar 2003 | A1 |
20030078465 | Pai et al. | Apr 2003 | A1 |
20030078671 | Lesniak et al. | Apr 2003 | A1 |
20030191528 | Quijano et al. | Oct 2003 | A1 |
20030198605 | Montgomery | Oct 2003 | A1 |
20030199974 | Lee et al. | Oct 2003 | A1 |
20040044364 | DeVries et al. | Mar 2004 | A1 |
20040068276 | Golden et al. | Apr 2004 | A1 |
20040122514 | Fogarty et al. | Jun 2004 | A1 |
20040138744 | Lashinski et al. | Jul 2004 | A1 |
20040148021 | Cartledge et al. | Jul 2004 | A1 |
20040193191 | Starksen et al. | Sep 2004 | A1 |
20040243230 | Navia et al. | Dec 2004 | A1 |
20040249391 | Cummins | Dec 2004 | A1 |
20040260393 | Randert et al. | Dec 2004 | A1 |
20040260394 | Douk et al. | Dec 2004 | A1 |
20050020696 | Montgomery et al. | Jan 2005 | A1 |
20050033325 | May et al. | Feb 2005 | A1 |
20050065550 | Starksen et al. | Mar 2005 | A1 |
20050090846 | Pedersen et al. | Apr 2005 | A1 |
20050096740 | Langberg et al. | May 2005 | A1 |
20050113910 | Paniagua et al. | May 2005 | A1 |
20050137692 | Haug et al. | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20050203549 | Realyvasquez | Sep 2005 | A1 |
20050222678 | Lashinski et al. | Oct 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050267572 | Schoon et al. | Dec 2005 | A1 |
20050283190 | Huitema et al. | Dec 2005 | A1 |
20050288778 | Shaoulian et al. | Dec 2005 | A1 |
20050288781 | Moaddeb et al. | Dec 2005 | A1 |
20060009737 | Whiting et al. | Jan 2006 | A1 |
20060020327 | Lashinski et al. | Jan 2006 | A1 |
20060122633 | To et al. | Jun 2006 | A1 |
20060129025 | Levine et al. | Jun 2006 | A1 |
20060155165 | Vanden Hoek et al. | Jul 2006 | A1 |
20060161169 | Nieminen et al. | Jul 2006 | A1 |
20060184240 | Jimenez et al. | Aug 2006 | A1 |
20060184242 | Lichtenstein | Aug 2006 | A1 |
20060195134 | Crittenden | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060241748 | Lee et al. | Oct 2006 | A1 |
20060282161 | Huynh et al. | Dec 2006 | A1 |
20070016287 | Cartledge et al. | Jan 2007 | A1 |
20070027533 | Douk | Feb 2007 | A1 |
20070038296 | Navia | Feb 2007 | A1 |
20070051377 | Douk et al. | Mar 2007 | A1 |
20070067027 | Moaddeb et al. | Mar 2007 | A1 |
20070073098 | Lenker et al. | Mar 2007 | A1 |
20070080188 | Spence et al. | Apr 2007 | A1 |
20070093854 | Kayan | Apr 2007 | A1 |
20070118215 | Moaddeb | May 2007 | A1 |
20070128132 | Piergallini et al. | Jun 2007 | A1 |
20070135913 | Moaddeb et al. | Jun 2007 | A1 |
20070142907 | Moaddeb et al. | Jun 2007 | A1 |
20070213812 | Webler et al. | Sep 2007 | A1 |
20070233239 | Navia et al. | Oct 2007 | A1 |
20070239272 | Navia et al. | Oct 2007 | A1 |
20070244553 | Rafiee et al. | Oct 2007 | A1 |
20070244554 | Rafiee et al. | Oct 2007 | A1 |
20070244555 | Rafiee et al. | Oct 2007 | A1 |
20070244556 | Rafiee et al. | Oct 2007 | A1 |
20070250161 | Dolan | Oct 2007 | A1 |
20070293942 | Mirzaee | Dec 2007 | A1 |
20080177380 | Starksen et al. | Jul 2008 | A1 |
20080177381 | Navia et al. | Jul 2008 | A1 |
20080200980 | Robin et al. | Aug 2008 | A1 |
20080243220 | Barker | Oct 2008 | A1 |
20080262513 | Stahler et al. | Oct 2008 | A1 |
20080262609 | Gross et al. | Oct 2008 | A1 |
20080306586 | Cartledge et al. | Dec 2008 | A1 |
20090088838 | Shaolian et al. | Apr 2009 | A1 |
20090118747 | Bettuchi et al. | May 2009 | A1 |
20090125098 | Chuter | May 2009 | A1 |
20090149872 | Gross et al. | Jun 2009 | A1 |
20090216322 | Le et al. | Aug 2009 | A1 |
20090222083 | Nguyen et al. | Sep 2009 | A1 |
20090238778 | Mordas et al. | Sep 2009 | A1 |
20090299470 | Rao et al. | Dec 2009 | A1 |
20100010616 | Drews et al. | Jan 2010 | A1 |
20100030014 | Ferrazzi | Feb 2010 | A1 |
20100063586 | Hasenkarn et al. | Mar 2010 | A1 |
20100121433 | Bolling et al. | May 2010 | A1 |
20100161047 | Cabiri | Jun 2010 | A1 |
20100185274 | Moaddeb et al. | Jul 2010 | A1 |
20100211166 | Miller et al. | Aug 2010 | A1 |
20100249920 | Bolling et al. | Sep 2010 | A1 |
20100266989 | Piergallilni et al. | Oct 2010 | A1 |
20100280605 | Hammer et al. | Nov 2010 | A1 |
20100286767 | Zipory et al. | Nov 2010 | A1 |
20110022168 | Cartledge | Jan 2011 | A1 |
20110027753 | Maurat et al. | Feb 2011 | A1 |
20110034953 | Milo | Feb 2011 | A1 |
20110066231 | Cartledge et al. | Mar 2011 | A1 |
20110093062 | Cartledge et al. | Apr 2011 | A1 |
20110106245 | Miller et al. | May 2011 | A1 |
20110106247 | Miller et al. | May 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110166649 | Gross et al. | Jul 2011 | A1 |
20110190879 | Bobo et al. | Aug 2011 | A1 |
20110208298 | Tuval et al. | Aug 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110257728 | Kuehn | Oct 2011 | A1 |
20110282361 | Miller et al. | Nov 2011 | A1 |
20110301698 | Miller et al. | Dec 2011 | A1 |
20110301699 | Saadat | Dec 2011 | A1 |
20120022557 | Cabiri et al. | Jan 2012 | A1 |
20120022644 | Reich et al. | Jan 2012 | A1 |
20120059458 | Buchbinder et al. | Apr 2012 | A1 |
20120095455 | Rodmond et al. | Apr 2012 | A1 |
20120123531 | Tsukashima | May 2012 | A1 |
20120136436 | Cabiri et al. | May 2012 | A1 |
20120165930 | Gifford, III et al. | Jun 2012 | A1 |
20120245604 | Tegzes | Sep 2012 | A1 |
20120310330 | Buchbinder et al. | Dec 2012 | A1 |
20130087598 | Surti | Apr 2013 | A1 |
20130116780 | Miller et al. | May 2013 | A1 |
20130166022 | Conklin | Jun 2013 | A1 |
20130204361 | Adams et al. | Aug 2013 | A1 |
20130226289 | Shaolian | Aug 2013 | A1 |
20130226290 | Yellin | Aug 2013 | A1 |
20130282114 | Schweich, Jr. et al. | Oct 2013 | A1 |
20130289718 | Tsukashima et al. | Oct 2013 | A1 |
20130289720 | Dobrilovic | Oct 2013 | A1 |
20130304197 | Buchbinder et al. | Nov 2013 | A1 |
20140005778 | Buchbinder et al. | Jan 2014 | A1 |
20140046433 | Kovalsky | Feb 2014 | A1 |
20140058505 | Bielefeld | Feb 2014 | A1 |
20140114407 | Rajamannan | Apr 2014 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150173987 | Albinmousa et al. | Jun 2015 | A1 |
20150351903 | Morriss et al. | Dec 2015 | A1 |
20160022419 | Yellin et al. | Jan 2016 | A1 |
20160038286 | Yellin et al. | Feb 2016 | A1 |
20160089235 | Yellin | Mar 2016 | A1 |
20160106420 | Foerster et al. | Apr 2016 | A1 |
20160120642 | Shaolian et al. | May 2016 | A1 |
20160120645 | Alon | May 2016 | A1 |
20170042670 | Shaolian et al. | Feb 2017 | A1 |
20170231763 | Yellin | Aug 2017 | A1 |
20180042723 | Yellin et al. | Feb 2018 | A1 |
Number | Date | Country |
---|---|---|
102014102653 | Sep 2015 | DE |
2600799 | Jun 2013 | EP |
2928538 | Oct 2015 | EP |
2967700 | Jan 2016 | EP |
3213715 | Sep 2017 | EP |
10-2004-0095482 | Nov 2004 | KR |
125062 | Feb 2013 | RU |
1990009153 | Feb 1993 | WO |
2003017874 | Mar 2003 | WO |
2003047467 | Jun 2003 | WO |
2005046488 | May 2005 | WO |
2009052427 | Apr 2009 | WO |
2009120764 | Oct 2009 | WO |
2010004546 | Jan 2010 | WO |
2010085659 | Jul 2010 | WO |
2011011443 | Jan 2011 | WO |
2011097355 | Aug 2011 | WO |
2012004679 | Jan 2012 | WO |
2012019052 | Feb 2012 | WO |
2012063228 | May 2012 | WO |
2012095159 | Jul 2012 | WO |
2012106354 | Aug 2012 | WO |
2012167095 | Dec 2012 | WO |
2013095816 | Jun 2013 | WO |
2013128436 | Sep 2013 | WO |
2013130641 | Sep 2013 | WO |
2013175468 | Nov 2013 | WO |
2014145399 | Sep 2014 | WO |
2014189509 | Nov 2014 | WO |
2014190329 | Nov 2014 | WO |
2014210600 | Dec 2014 | WO |
2015132668 | Sep 2015 | WO |
2018035118 | Feb 2018 | WO |
Entry |
---|
International Search Report and Written Opinion for PCT/US2018/022910 dated May 23, 2018. |
European Search Report in EP 17155803.4 dated Aug. 9, 2017. |
International Search Report and Written Opinion for PCT/US2014/044920 dated Dec. 24, 2014. |
International Search Report and Written Opinion for PCT/US2011/046659 dated Jun. 4, 2012. |
International Search Report and Written Opinion for PCT/US2012/040481 dated Dec. 6, 2012. |
International Search Report and Written Opinion for PCT/US2013/042275 dated Feb. 20, 2014. |
International Search Report and Written Opinion for PCT/US2013/073552 dated Mar. 6, 2014. |
International Search Report and Written Opinion for PCT/US2014/039545 dated Oct. 22, 2014. |
International Search Report and Written Opinion for PCT/US2014/030163 dated Aug. 27, 2014. |
International Search Report and Written Opinion for PCT/US2013/058102 dated Apr. 21, 2014. |
International Search Report and Written Opinion for PCT/US2013/028065 dated Jun. 27, 2013. |
Lendlein et al., Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications, May 31, 2002, Science 296:1673-1676. |
Supplemental European Search Report and Written Opinion for EP 12793292.9 dated Dec. 1, 2014. |
Supplemental European Search Report and Written Opinion for EP 14762806.9 dated Jul. 29, 2016. |
International Search Report and Written Opinion for PCT/US2017/046933 dated Dec. 21, 2017. |
Communication pursuant to Article 94(3) EPC for EP 14801009.3 dated Sep. 27, 2018. |
Supplementary Partial European Search Report for EP 13755441 dated Nov. 3, 2015. |
International Search Report and Written Opinion for PCT2019/064289 dated Feb. 5, 2020. |
17841988.3, Extended European Search Report, dated Dec. 16, 2019 ,8 pages. |
PCT/US2017/046933, International Search Report and Written Opinion, dated Dec. 21, 2017 ,10 pages. |
Number | Date | Country | |
---|---|---|---|
20180042723 A1 | Feb 2018 | US |
Number | Date | Country | |
---|---|---|---|
62375079 | Aug 2016 | US |